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Abstract  
AIM: This study aims to evaluate the efficacy of Methotrexate (MTX) alone and combined therapy with Etanercept 
(ETN) and Methotrexate in patients with active rheumatoid arthritis (RA). 
METHODS: In the randomised control study, conducted in the period from March 2014 until March 2016, we 
evaluated the efficacy of the treatment of patients with RA with MTX as monotherapy and combination treatment 
with MTX and ETN. In the Clinic of Rheumatology in Prishtina, 90 adult patients with RA were treated in 
combination with ETN (doses of 50 mg subcutaneously/weekly), with oral MTX (doses up to 20 mg weekly), and 
MTX alone (doses up to 20 mg weekly) during this period of two years. Clinical response was assessed using 
European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) Criteria and the 
Disease Activity Score (DAS28). Radiographic changes were measured in the beginning and at the end of the 
study using Larsen’s method. 
RESULTS: Of the cohort groups of 90 patients, mean age of 55.63, 15 patients, (16.6 %) were treated with 
combined therapy (ETN plus MTX) and 75 patients (83.3%) with monotherapy (MTX). After two years of treatment 
the group with combined therapy resulted with improvement of acute phase reactants as erythrocyte 
sedimentation rate (ESR) for the first hour (41.1 vs. 10.3 mm/hour) and C - reactive protein (CRP) (40.8 vs. 6 
mg/liter), and compared to the group treated with monotherapy, there were no significant changes (ESR: 45.7 vs 
34.3 mm/hour; CRP: 48 vs 24 mg/liter). Before the treatment, the severity of the disease was high, wherein the 
group with combined therapy DAS28 was 5.32, compared to the monotherapy group whom DAS28 was 5.90. 
After 2 years of treatment, we had significant changes in the results of DAS28, wherein the group treated with 
ETN plus MTX DAS28 was 2.12 ± 0.15, while in the group of patients treated with MTX DAS28 were 3.75 ± 0.39 
(t = 13.03; df = 58; p < 0.0001). The group with combined therapy showed no evidence of radiographic 
progression comparing to the group of patients with monotherapy. 
CONCLUSIONS: Based on our results achieved during 2 years we can conclude that ETN in combination with 
MTX reduced disease activity, slowed radiographic progression and improved clinical manifestations more 
effectively than MTX alone. No serious adverse events were noticed in the group with combination treatment. 
 
 
 
 
 
 
 
Introduction 
 
Rheumatoid arthritis (RA) is an autoimmune 
disorder with unknown aetiology, characterised by 
symmetric, erosive synovitis and, sometimes 
multisystem involvement. The prevalence is 1 - 2% 
worldwide. Both, incidence and prevalence of 
rheumatoid arthritis, are two to three times higher in 
women than in men [1] [2]. The treatment goal is 
achieving the lowest level of activity of the disease 
and longest remission, minimization of the joint 
damage, maintaining physical function and quality of 
life. Treatment of RA contains a program that includes 
medical, social and emotional support for the patients. 
ETN is effective in reducing the signs and symptoms 
of RA, as well as in slowing or halting the radiographic 
damage when used either as a monotherapy or in 
combination with MTX. ETN binds TNF in circulation 
and in the joint, preventing interaction with cell surface 
TNF receptors, thereby reducing TNF activity [3] [4] 
[5]. 
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This study aims to evaluate the efficacy of 
Methotrexate (MTX) as a monotherapy versus 
combined therapy with Etanercept (ETN) and 
Methotrexate (MTX), in patients with active 
rheumatoid arthritis (RA). 
 
 
Patients and Methods 
 
In this randomised controlled study conducted 
during a period of two years, from March 2014 to 
March 2016, we have evaluated the efficacy of 
treatment of patients with RA treated with MTX alone 
and the combination of MTX and ETN.  
Patients were diagnosed with RA fulfilling 
criteria of European League against Rheumatism 
(EULAR)/American College of Rheumatology (ACR) 
and disease duration of at least one year [6]. Patients 
included in the study were treated with DMARDs such 
as Sulfasalazine and Hydroxychloroquine and they did 
not have a satisfactory response to the therapy. The 
youngest patient included in the study was aged 29 
years, with function class I - III (ACR), with 8 swollen 
and 10 painful joints; erythrocyte sedimentation rate 
(ESR) of 25 mm/hour, C - reactive protein (CRP) level 
of 12 mg/liter, and morning stiffness more than 30 
minutes. Pain on a visual analog scale (VAS: 0 - 100 
mm) was evaluated for each patient, clinical response 
was assessed using American College of 
Rheumatology (ACR) criteria for 20% improvement 
ACR20, the ACR50 and the ACR70 in RA, and the 
Disease Activity Score in 28 joints (DAS28) [7][8][9]. 
Patients with a history of previous hepatitis, 
tuberculosis and active infectious disease were 
excluded from the study. 
Study protocol Included patients treated in 
combination with ETN and MTX (doses of 50 mg 
subcutaneously weekly), oral MTX (doses up to 20 mg 
weekly), and alone MTX (doses up to 20 mg weekly) 
in two years, in the Clinic for Rheumatology in 
Prishtina. Patients received a low dose of 
corticosteroids at the beginning of the treatment 
during 3 months (initial dose of 20 mg and the 
maintenance dose was 7.5 mg). Radiographic 
changes were measured at the beginning and the end 
of the study with Larsen’s methodology 1995, using a 
scoring system that attributes 0 to 5 points of each 
synovial joint evaluated on a radiograph [10] [11].
 
Safety assessments were based on reported adverse 
events, laboratory tests and physical routine 
examinations. The study was approved by the Ethical 
Committee of the University Clinical Center of Kosovo, 
and a written informed consent has been obtained 
from each patient before he/she entered the study. 
All data were expressed as the mean ± 
standard deviation (SD) and percentages. The 
significant difference from each group was analysed 
by t-test of proportion, Superman's Correlation-test for 
calculation the radiographic changes. Statistical 
analyses were performed using the statistical SPSS. 
Significance was set up at p < 0.05.  
 
 
Results 
 
Out of the total number of 90 patients 
included in the study, 15 were males, and 75 were 
females, with a mean age of 55.64 years. Fifteen 
patients or 16.6 % were treated with combined 
therapy (ETN plus MTX) and 75 patients or 83.3% 
with monotherapy (MTX). The group of combined 
therapy showed improvement of acute phase 
reactants compared to the group treated with MTX 
alone. ESR (normal values < 10 mm/hour), of the first 
group (ETN plus MTX) in the first hour of ESR was 
41.1 vs. 10.3 mm/hour and CRP (normal value < 6 
mg/liter) was 40.8 vs. 6 mg/liter (p = 0.001) compared 
to the second (MTX alone) showed no significant 
changes (ESR: 45.7 vs 34.3 mm/hour; CRP: 48 vs 24 
mg/liter), p = 0.17. 
Patients treated with combined therapy 
achieved ACR20, ACR50 and ACR70 better response 
rather than patients treated with monotherapy (MTX). 
ACR20 responses were achieved at the level of 90% 
in patients with combined therapy group (ETN plus 
MTX) vs 84% of the monotherapy group (MTX) p = 
0.63. ACR50 responses were achieved by 70% of the 
combination therapy group vs 46% of the 
monotherapy group p = 0.17. ACR70 responses were 
achieved by 40% of the combination group vs 16% of 
the monotherapy group p = 0.089. The severity of the 
disease, measured before treatment by DAS Score 
was high. The group that was treated with combined 
therapy (ETN plus MTX) had DAS28 of 5.32, whereas 
the group with monotherapy of MTX had DAS28 of 
5.90. After 2 years of treatment, we had significant 
changes in the results of DAS28. The group treated 
with ETN plus MTX had DAS28 of 2.12 ± 0.15, while 
the group of patients treated with MTX had DAS28 of 
3.75 ± 0.39 (t = 13.03; df = 58; p < 0.0001) (Table 1). 
Table 1: Characteristics of treatment of RA with Methotrexate 
and combined therapy with Etanercept and Methotrexate 
  Methotrexate 
(MTX) 
Etanercept and 
Methotrexate 
(ETN + MTX) 
T-test of 
proportion 
t-test p-value 
N (%) N (%)  
75 (83.3%) 15 (16.6%) 
Female 63 (84%) 9 (60%) 
Male 12 (16%) 6 (40%) 
American College of Rheumatology (ACR) criteria 
ACR20 84% 90% t=0.49; df=58; 
p=0.63 
ACR50 46% 70% t=1.39; df=58; 
p=0.17 
ACR70 16% 40% t=1.73; df=58; 
p=0.089 
Disease Activity Score (DAS28)   
Before treatment 5.9 ± 0.49 5.32 ± 0.26  
After treatment 3.75 ± 0.39 2.12 ± 0.15 t=13.03; df=58; 
p<0.0001 
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Radiography of hands and feet were done at 
the beginning and the end of the study. The scoring 
was done by total Larsen’s score in 32 joints (total 
Larsen score range is 0 - 160). Mean value of total 
Larsen’s score in the first group of patients, treated 
with ETN + MTX at the beginning of the study was 
2.58, whereas at the end of the study was 3.54. In the 
second group of patients treated with MTX, at the 
beginning of the study, the mean value of Larsen’s 
score was 2.84 whereas at 24 months 3.95. According 
to the Larsen’s method, in the group of combined 
therapy showed no evidence of radiographic 
progression comparing to the group of monotherapy 
(p < 0.010). 
During the treatment, in the group of patients 
with monotherapy 8 cases were reported for transitory 
adverse effects such as nausea, vomiting, and 
gastrointestinal ache. In the group of combined 
therapy, there is no evidence of serious adverse 
events, infectious or noninfectious that was noticed. 
During the study, none deaths were reported.  
 
 
Discussion  
 
Our study is based on the comparison of 
results from the treatment of RA with combined 
therapy (ETN plus MTX) and monotherapy (MTX). 
Results confirm the significant advantage of combined 
therapy over monotherapy. DMARD medications are 
utilised much earlier in the treatment of RA, due to 
their efficacy in retarding erosive damages. Biologics 
produce rapid and sustained amelioration of the signs 
and symptoms of RA, retard radiological progression, 
and improve quality of life more effectively than 
DMARDs [12]. 
Our study showed that combined therapy had 
a statistically significant benefit compared to the 
monotherapy for ACR20, ACR50 and ACR70 
response. It also shows the significant advantage of 
combined therapy over monotherapy in controlling the 
disease activity measured by DAS28 Score. DAS28 
was obviously lower in the group treated with 
combined therapy compared to the group treated with 
monotherapy. 
Different authors showed the improvement of 
RA using combined therapy (ETN + MTX), e.g. 
Weinblatt ME et al., (1999). A trial of Etanercept, a 
recombinant tumour necrosis factor receptor: Fc 
fusion protein, in patients with rheumatoid arthritis 
receiving MTX. The authors show that in 89 RA’s, 
patients treated with ETN showed more efficacy of 
ETN when used a combination treatment with MTX 
over 6 months of treatment. Our results are similar to 
recent studies [13]. 
The reason we conducted this study was to 
improve the care of our patients. Our study confirmed 
that combined therapy had given better improvement. 
Clinical studies suggest that etanercept is safe and 
effective as a long-term therapy for the treatment of 
RA, and the risk and benefit ratio of continuous 
etanercept treatment remains beneficial [14] [15] [16]. 
Limitations of the study include the small 
number of patients in the group of combined therapy, 
because of the economic limitation conditions of 
applying etanercept to other patients with RA. 
Furthermore, studies with higher number of patients 
need to be done.  
According to our results, we can conclude that 
etanercept in combination with methotrexate reduced 
disease activity, slowed radiographic progression and 
improved clinical manifestations more effectively than 
methotrexate alone within 2 years. During the 
treatment, no serious adverse events were noticed 
with a combination treatment of etanercept and 
methotrexate.  
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